MagForce, a leading medical device company in the field of nanomedicine focused on oncology, has announced that the Department of Neurosurgery at Kiel University Hospital (UKSH), headed by Professor Dr. Hubertus Maximilian Mehdorn, has initiated NanoTherm therapy in the commercial setting for the treatment of brain cancers.
After the start of commercial treatments of brain cancers at the University Hospital in Munster in February, this marks another milestone for MagForce with now two world class medical centres offering NanoTherm therapy also in the commercial setting.
"Since we announced the first commercial patient in February this year based on our European approval for the treatment of brain cancer, we have observed a significantly increased interest of patients, national as well as international, for the treatment with our innovative NanoTherm therapy in Germany. We are especially pleased with the successful interaction with the key opinion leaders in the medical community. Preparations for the approval process in the USA both for brain cancer and prostate cancer are well on track, hence, 2015 is set to be a transformational year for MagForce, marking first commercial revenues and global expansion," commented Dr. Ben J. Lipps, CEO of MagForce.
